UBS Group
AVXL icon

UBS Group’s Anavex Life Sciences AVXL Stock Holding History

UBS Group’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-20,000
Closed -$186K – 9288
2023
Q4 		$186K Buy
+20,000
New +$138K ﹤0.01% 5819
2019
Q1 		– Sell
-9,900
Closed -$15K – 7719
2018
Q4 		$15K Hold
9,900
– – ﹤0.01% 6982
2018
Q3 		$27K Hold
9,900
– – ﹤0.01% 6610
2018
Q2 		$26K Buy
+9,900
New +$27.7K ﹤0.01% 6501

Other funds holding AVXL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
SF
Summit Financial Parsippany, New Jersey $7.85B AUM 20.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

UBS Group's AVXL Position: Q1 2026 in Review

UBS Group increased its Anavex Life Sciences (AVXL) stake by 24% in Q1 2026, buying an estimated $479K and bringing the position to 569,956 shares worth $1.75M. The position accounts for ﹤0.01% of the portfolio, ranked #5092.

UBS Group first reported a position in AVXL in Q4 2015 and has held it in 42 quarters since. The position peaked at $5.22M in Q1 2025. 190 funds tracked by Wall St. Rank hold AVXL as of Q1 2026.

  • UBS Group held 569,956 shares of Anavex Life Sciences worth $1.75M as of Q1 2026.
  • UBS Group bought 110,562 Anavex Life Sciences shares in Q1 2026, an estimated $479K.
  • Anavex Life Sciences made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #5092 holding.
  • UBS Group first reported a position in Anavex Life Sciences in Q4 2015 and has held it in 42 quarters since.
  • UBS Group's Anavex Life Sciences position peaked at $5.22M in Q1 2025.
  • 190 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.